CR Strategy & Innovation, Novartis AG
With close to 20 years of experience in CR and business ethics, Michael is currently having responsibilities for CR Strategy and Innovation at Novartis AG. He has significant experience in CR Strategy, access to healthcare, inclusive business model innovation, base of the pyramid strategies, measurement & evaluation, investor relations re ESG, stakeholder engagement, materiality, impact valuation, Human Rights and behavior-based integrity & compliance management. Michael is strongly involved in the development and deployment of Novartis Social Businesses such as Novartis Access, Healthy Families etc. Michael is the Secretary of the CR Board of Novartis.
He is author and editor of articles and books in the areas of CR, social entrepreneurship, integrity management, risk and good governance and has a PhD with honors, awarded for his academic work (PhD thesis) with the Max Weber-Price for Business Ethics (2006).
Michael is a Social Entrepreneur in Residence at INSEAD and a recognized lecturer and speaker to students and executives at leading universities and business schools (e.g. INSEAD, IMD, Thunderbird, Cambridge University, HSG, Copenhagen Business School etc.).
He also extensively collaborated with faculty from Harvard Business School, Thunderbird et al. over a number of years to build skills of Novartis management population on topics such as integrity & compliance management and inclusive business model innovation.
Economic Opportunity • Education • Health • Health Delivery • Human Rights • Livelihoods • Living Conditions • Peace and Human Rights • Responsible Supply Chains • Smallholder Productivity • Standards • Sustainable Markets • Women's and Girls' Education
Caribbean, Central America, Central and Southern Asia, Eastern and Southern Africa, Eastern Asia, Europe, Middle East and North Africa, North America, Oceania, South America, Southeast Asia, West and Central Africa